b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">30179153</PMID>\n        <DateCompleted>\n            <Year>2019</Year>\n            <Month>04</Month>\n            <Day>09</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>03</Month>\n            <Day>09</Day>\n        </DateRevised>\n        <Article PubModel="Print">\n            <Journal>\n                <ISSN IssnType="Electronic">2046-4924</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>22</Volume>\n                    <Issue>48</Issue>\n                    <PubDate>\n                        <Year>2018</Year>\n                        <Month>08</Month>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Health technology assessment (Winchester, England)</Title>\n                <ISOAbbreviation>Health Technol Assess</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Triple versus guideline antiplatelet therapy to prevent recurrence after acute ischaemic stroke or transient ischaemic attack: the TARDIS RCT.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>1-76</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.3310/hta22480</ELocationID>\n            <Abstract>\n                <AbstractText Label="BACKGROUND">Two antiplatelet agents are better than one for preventing recurrent stroke after acute ischaemic stroke or transient ischaemic attack (TIA). Therefore, intensive treatment with three agents might be better still, providing it does not cause undue bleeding.</AbstractText>\n                <AbstractText Label="OBJECTIVE">To compare the safety and efficacy of intensive therapy with guideline antiplatelet therapy for acute ischaemic stroke and TIA.</AbstractText>\n                <AbstractText Label="DESIGN">International prospective randomised open-label blinded end-point parallel-group superiority clinical trial.</AbstractText>\n                <AbstractText Label="SETTING">Acute hospitals at 106 sites in four countries.</AbstractText>\n                <AbstractText Label="PARTICIPANTS">Patients &gt;\xe2\x80\x8950 years of age with acute non-cardioembolic ischaemic stroke or TIA within 48 hours of ictus (stroke).</AbstractText>\n                <AbstractText Label="INTERVENTIONS">Participants were allocated at random by computer to 1 month of intensive (combined aspirin, clopidogrel and dipyridamole) or guideline (combined aspirin and dipyridamole, or clopidogrel alone) antiplatelet agents, and followed for 90 days.</AbstractText>\n                <AbstractText Label="MAIN OUTCOME MEASURES">The primary outcome was the incidence and severity of any recurrent stroke (ischaemic, haemorrhagic; assessed using the modified Rankin Scale) or TIA within 90 days by blinded telephone follow-up. Analysis using ordinal logistic regression was by intention to treat. Other outcomes included bleeding and its severity, death, myocardial infarction (MI), disability, mood, cognition and quality of life.</AbstractText>\n                <AbstractText Label="RESULTS">The trial was stopped early on the recommendation of the Data Monitoring Committee after recruitment of 3096 participants (intensive, <i>n</i>\xe2\x80\x89=\xe2\x80\x891556; guideline, <i>n</i>\xe2\x80\x89=\xe2\x80\x891540) from 106 hospitals in four countries between April 2009 and March 2016. The incidence and severity of recurrent stroke or TIA did not differ between intensive and guideline therapy in 3070 (99.2%) participants with data [93 vs. 105 stroke/TIA events; adjusted common odds ratio 0.90, 95% confidence interval (CI) 0.67 to 1.20; <i>p</i>\xe2\x80\x89=\xe2\x80\x890.47]. Major (encompassing fatal) bleeding was increased with intensive as compared with guideline therapy [39 vs. 17 participants; adjusted hazard ratio (aHR) 2.23, 95% CI 1.25 to 3.96; <i>p</i>\xe2\x80\x89=\xe2\x80\x890.006]. There were no differences between the treatment groups in all-cause mortality, or the composite of death, stroke, MI and major bleeding (aHR 1.02, 95% CI 0.77 to 1.35; <i>p</i>\xe2\x80\x89=\xe2\x80\x890.88).</AbstractText>\n                <AbstractText Label="LIMITATIONS">Patients and investigators were not blinded to treatment. The comparator group comprised two guideline strategies because of changes in national guidelines during the trial. The trial was stopped early, thereby reducing its statistical power.</AbstractText>\n                <AbstractText Label="CONCLUSIONS">The use of three antiplatelet agents is associated with increased bleeding without any significant reduction in recurrence of stroke or TIA.</AbstractText>\n                <AbstractText Label="FUTURE WORK">The safety and efficacy of dual antiplatelet therapy (combined aspirin and clopidogrel) versus aspirin remains to be defined. Further research is required on identifying individual patient response to antiplatelets, and the relationship between response and the subsequent risks of vascular recurrent events and bleeding complications.</AbstractText>\n                <AbstractText Label="TRIAL REGISTRATION">Current Controlled Trials ISRCTN47823388.</AbstractText>\n                <AbstractText Label="FUNDING">This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in <i>Health Technology Assessment</i>; Vol. 22, No. 48. See the NIHR Journal Library website for further project information. The Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke (TARDIS) vanguard phase was funded by the British Heart Foundation (grant PG/08/083/25779, from 1 April 2009 to 30 September 2012) and indirect funding was provided by the Stroke Association through its funding of the Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK. There was no commercial support for the trial and antiplatelet drugs were sourced locally at each site. The trial was sponsored by the University of Nottingham.</AbstractText>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Bath</LastName>\n                    <ForeName>Philip M</ForeName>\n                    <Initials>PM</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Stroke, Nottingham University Hospitals NHS Trust, Nottingham, UK.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Woodhouse</LastName>\n                    <ForeName>Lisa J</ForeName>\n                    <Initials>LJ</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Appleton</LastName>\n                    <ForeName>Jason P</ForeName>\n                    <Initials>JP</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Stroke, Nottingham University Hospitals NHS Trust, Nottingham, UK.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Beridze</LastName>\n                    <ForeName>Maia</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Neurology, Hospital of War Veterans, Tbilisi, Georgia.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Christensen</LastName>\n                    <ForeName>Hanne</ForeName>\n                    <Initials>H</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Neurology, Bispebjerg and Frederiksberg Hospital, University of Copenhagen, Copenhagen, Denmark.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Dineen</LastName>\n                    <ForeName>Robert A</ForeName>\n                    <Initials>RA</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Radiological Sciences, Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Flaherty</LastName>\n                    <ForeName>Katie</ForeName>\n                    <Initials>K</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Duley</LastName>\n                    <ForeName>Lelia</ForeName>\n                    <Initials>L</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>England</LastName>\n                    <ForeName>Timothy J</ForeName>\n                    <Initials>TJ</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Vascular Medicine, Division of Medical Sciences and Graduate Entry Medicine, University of Nottingham, Nottingham, UK.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Havard</LastName>\n                    <ForeName>Diane</ForeName>\n                    <Initials>D</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Heptinstall</LastName>\n                    <ForeName>Stan</ForeName>\n                    <Initials>S</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>James</LastName>\n                    <ForeName>Marilyn</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Health Economics, Division of Rehabilitation and Ageing, University of Nottingham, Nottingham, UK.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Kasonde</LastName>\n                    <ForeName>Chibeka</ForeName>\n                    <Initials>C</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Lowdham Medical Centre, Nottingham, UK.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Krishnan</LastName>\n                    <ForeName>Kailash</ForeName>\n                    <Initials>K</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Stroke, Nottingham University Hospitals NHS Trust, Nottingham, UK.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Markus</LastName>\n                    <ForeName>Hugh S</ForeName>\n                    <Initials>HS</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Montgomery</LastName>\n                    <ForeName>Alan A</ForeName>\n                    <Initials>AA</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Pocock</LastName>\n                    <ForeName>Stuart</ForeName>\n                    <Initials>S</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Medical Statistics Unit, London School of Hygiene &amp; Tropical Medicine, London, UK.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Randall</LastName>\n                    <ForeName>Marc</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Neurology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Ranta</LastName>\n                    <ForeName>Annamarei</ForeName>\n                    <Initials>A</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Neurology, Wellington Hospital and University of Otago, Wellington, New Zealand.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Robinson</LastName>\n                    <ForeName>Thompson G</ForeName>\n                    <Initials>TG</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Cardiovascular Sciences, University of Leicester, Leicester, UK.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Scutt</LastName>\n                    <ForeName>Polly</ForeName>\n                    <Initials>P</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Venables</LastName>\n                    <ForeName>Graham S</ForeName>\n                    <Initials>GS</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Neurology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Sprigg</LastName>\n                    <ForeName>Nikola</ForeName>\n                    <Initials>N</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Stroke, Nottingham University Hospitals NHS Trust, Nottingham, UK.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <DataBankList CompleteYN="Y">\n                <DataBank>\n                    <DataBankName>ISRCTN</DataBankName>\n                    <AccessionNumberList>\n                        <AccessionNumber>ISRCTN47823388</AccessionNumber>\n                    </AccessionNumberList>\n                </DataBank>\n            </DataBankList>\n            <GrantList CompleteYN="Y">\n                <Grant>\n                    <GrantID>10/104/24</GrantID>\n                    <Acronym>DH_</Acronym>\n                    <Agency>Department of Health</Agency>\n                    <Country>United Kingdom</Country>\n                </Grant>\n                <Grant>\n                    <GrantID>PG/08/083/25779</GrantID>\n                    <Acronym>BHF_</Acronym>\n                    <Agency>British Heart Foundation</Agency>\n                    <Country>United Kingdom</Country>\n                </Grant>\n            </GrantList>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n                <PublicationType UI="D016448">Multicenter Study</PublicationType>\n                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>\n                <PublicationType UI="D013485">Research Support, Non-U.S. Gov\'t</PublicationType>\n            </PublicationTypeList>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>England</Country>\n            <MedlineTA>Health Technol Assess</MedlineTA>\n            <NlmUniqueID>9706284</NlmUniqueID>\n            <ISSNLinking>1366-5278</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D010975">Platelet Aggregation Inhibitors</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>64ALC7F90C</RegistryNumber>\n                <NameOfSubstance UI="D004176">Dipyridamole</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>A74586SNO7</RegistryNumber>\n                <NameOfSubstance UI="D000077144">Clopidogrel</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>R16CO5Y76E</RegistryNumber>\n                <NameOfSubstance UI="D001241">Aspirin</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D001241" MajorTopicYN="N">Aspirin</DescriptorName>\n                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000077144" MajorTopicYN="N">Clopidogrel</DescriptorName>\n                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D004176" MajorTopicYN="N">Dipyridamole</DescriptorName>\n                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName>\n                <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D002546" MajorTopicYN="N">Ischemic Attack, Transient</DescriptorName>\n                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>\n                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>\n                <QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D010975" MajorTopicYN="N">Platelet Aggregation Inhibitors</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>\n                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>\n                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D012107" MajorTopicYN="N">Research Design</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D020521" MajorTopicYN="N">Stroke</DescriptorName>\n                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>\n                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>\n                <QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName>\n            </MeshHeading>\n        </MeshHeadingList>\n        <CoiStatement>Philip M Bath reports grants from the British Heart Foundation and National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme during the conduct of the study, and he is a shareholder in Platelet Solutions Ltd (Nottingham, UK). He also notes personal fees from Diamedica (Minneapolis, MN, USA), Nestl\xc3\xa9 (Vevey, Switzerland), Phagenesis Ltd (Manchester, UK), ReNeuron (Bridgend, UK), Athersys (Cleveland, OH, USA), and Covidien (Zurich, Switzerland) outside the submitted work. Robert A Dineen reports a grant from the British Heart Foundation during the conduct of the study. Hugh S Markus reports grants from the NIHR HTA programme during the conduct of the study. Alan A Montgomery is a member of the NIHR HTA Clinical Evaluation and Trials Funding Board.</CoiStatement>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2018</Year>\n                <Month>9</Month>\n                <Day>5</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2018</Year>\n                <Month>9</Month>\n                <Day>5</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2019</Year>\n                <Month>4</Month>\n                <Day>10</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">30179153</ArticleId>\n            <ArticleId IdType="doi">10.3310/hta22480</ArticleId>\n            <ArticleId IdType="pmc">PMC6139477</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'